Actively Recruiting
Evaluating PET Imaging With 18FFluorbetazine Injection for Detecting Amyloid Beta Plaques in Normal, MCI, and Alzheimers Participants
Led by HTA Co., Ltd. · Updated on 2026-08-14
400
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multicenter phase III clinical trial to assess how well PET scans using 18FFluorbetazine injection can detect amyloid beta A plaques in the brains of people with normal cognitive function, mild cognitive impairment MCI caused by Alzheimers disease AD, and AD dementia. The study aims to evaluate the diagnostic accuracy and safety of this imaging method for these groups. Participants receive a single intravenous injection of 18FFluorbetazine followed by PET imaging to visualize A plaque deposition. The study focuses on measuring sensitivity and specificity of the PET images compared to established standards. Researchers also analyze brain uptake patterns and image consistency among readers during the one-year follow-up period. During the trial, participants undergo PET scans and brain MRIs to assess plaque accumulation and brain structure. Researchers collect imaging data including standardized uptake value ratios and gray-to-white matter ratios. The primary outcome measures how accurately PET imaging identifies amyloid plaques. Safety and tolerability of the injection are also monitored throughout the study, which lasts up to one year from imaging.
CONDITIONS
Brief Title
A Clinical Study Evaluating the Diagnostic Performance and Safety of PET for the Deposition of Aβ Plaques in the Brain of Participants With Normal Cognitive Function, MCI and AD Using [18F]Fluorbetazine Injection
Research Team
X
Xiaomin Xu, Master
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here